The Ischemia Trial - CCC
缺血试验 - CCC
基本信息
- 批准号:9067491
- 负责人:
- 金额:$ 548.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-07-22 至 2019-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAffectAmericanAnatomyAngiographyAngioplastyAreaAttitudeBlindedBypassCardiacCardiac Catheterization ProceduresCardiovascular systemCaringCatheterizationCause of DeathCessation of lifeClinicalClinical TrialsComparative StudyCoronaryCoronary ArteriosclerosisCoronary StenosisCoronary arteryDataDiabetes MellitusDiseaseDoseDrug EvaluationEffectivenessEligibility DeterminationEnrollmentEvaluationEventFrequenciesFutureGoalsHealthHealth PolicyHealth ResourcesHeart ArrestHeart failureHospitalizationImageIncidenceIntentionInternationalInvestigationIschemiaKnowledgeLeftLeft Ventricular Ejection FractionLesionLife StyleMedicalMyocardial InfarctionMyocardial IschemiaOperative Surgical ProceduresOutcomePatientsPharmaceutical PreparationsPhysiciansProspective StudiesQuality of lifeQuestionnairesRandomizedRandomized Clinical TrialsRandomized Controlled TrialsReflex actionRefractoryRiskRoleSelection BiasSeveritiesSiteStenosisStentsStressStress TestsStrokeSymptomsTestingThallium Myocardial Perfusion Imaging Stress TestTherapeuticTimeTranslatingUnited StatesUnstable anginaabstractingacute coronary syndromebaseclinical practicecohortcomparative effectivenesscostcost effectivenessdisabilityeconomic outcomeeffectiveness researchfollow-uphigh riskimprovedindividual patientmeetingspreventprospectiverandomized trialreduce symptomsroutine caretreatment group
项目摘要
DESCRIPTION (provided by applicant):
The long-term objective of the proposed trial, International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA), is to define the role of an invasive approach in patients with stable ischemic heart disease (SIHD) and substantial ischemia. The trial hypothesis is that cardiac catheterization followed by complete revascularization plus optimal medical therapy (OMT) is superior to OMT alone as the management strategy for patients with moderate-severe ischemia on stress imaging. The primary endpoint will be time to cardiovascular death, myocardial infarction (MI), or hospitalization for unstable angina, resuscitated cardiac arrest, or heart failure. The hypothesis that the invasive strategy will improve quality of life will also be tested. Cost-effectiveness will be assessed.
The COURAGE and BARI 2D trials found that an initial management strategy of coronary revascularization did not reduce the risk of death or MI compared with OMT alone in SIHD patients selected on the basis of coronary anatomy. These data raise the question whether cardiac catheterization (cath) is required in stable patients. Cath in such patients usually leads to revascularization. Although COURAGE and BARI 2D included a broad range of severity of myocardial ischemia on stress testing, most patients had mild-moderate ischemia. Observational data suggest that revascularization of patients with moderate-severe ischemia is associated with a lower likelihood of death and MI; this is not observed in patients with lesser degrees of ischemia. Only about half of patients with moderate-severe ischemia are referred for cath. It is unknown whether use rates for cath and revascularization are appropriate for optimal patient management in the era of modern medical therapy (particularly with high dose statins and antiplatelet therapy). This issue cannot be resolved using available data because prior clinical trials in SIHD have enrolled patients after cath, at which point there is substantial selection bias for enrollment based on coronary anatomy. Given the potential for improved survival and fewer cardiac events as a result of revascularization and the significant expense and risks associated with invasive management, the role of an invasive strategy is critically important to define. Defining that role is among the top 100 US priorities for comparative effectiveness research.
The proposed ISCHEMIA trial will be a prospective, multicenter, international, randomized, controlled trial that will directly address the need for an invasive strategy-cath and revascularization-in patients with SIHD. A total of 8,000 patients with moderate-severe ischemia and left ventricular ejection fraction >35% will be enrolled after stress imaging from more than 400 sites. Based on the need to exclude significant left main coronary artery disease, patients who meet eligibility criteria will undergo blinded coronary CT angiography. Patients will be randomized to an invasive group that will undergo routine cath with optimal revascularization, if feasible, plus OMT or to a group that receives OMT alone.
描述(由申请人提供):
这项拟议试验的长期目标是确定侵入性方法在稳定性缺血性心脏病(SIHD)和实质性缺血患者中的作用,这项试验名为《医疗和侵入性方法健康有效性比较研究》。试验假说是,在负荷成像上,心导管置入术+完全血运重建加最佳药物治疗(OMT)优于单纯OMT作为中重度缺血患者的治疗策略。主要终点将是心血管死亡、心肌梗死(MI)或因不稳定心绞痛、复苏心脏骤停或心力衰竭而住院的时间。侵入性策略将改善生活质量的假设也将得到检验。将对成本效益进行评估。
CORAGE和BARI 2D试验发现,在根据冠状动脉解剖选择的SIHD患者中,与单纯OMT相比,冠状动脉血管重建术的初始管理策略并不能降低死亡或心肌梗死的风险。这些数据提出了在病情稳定的患者中是否需要心导管插入术(Cath)的问题。此类患者的冠状动脉介入治疗通常会导致血运重建。尽管CORAGE和BARI 2D在负荷测试中包括了广泛的心肌缺血严重程度,但大多数患者都有轻到中度的心肌缺血。观察数据表明,中-重度缺血患者的血运重建与较低的死亡和心肌梗死的可能性有关;这在缺血程度较轻的患者中没有观察到。只有大约一半的中-重度缺血患者需要进行冠状动脉介入治疗。在现代医学治疗(特别是大剂量他汀类药物和抗血小板治疗)的时代,导管和血管重建术的使用率是否适合于最佳的患者管理尚不清楚。这个问题不能用现有的数据解决,因为以前的SIHD临床试验在CATH后招募了患者,在这一点上,基于冠状动脉解剖的入选存在很大的选择偏差。考虑到血运重建有可能提高存活率和减少心脏事件,以及与侵入性管理相关的巨额费用和风险,确定侵入性策略的作用至关重要。界定这一角色是美国比较有效性研究的100大优先事项之一。
拟议的缺血试验将是一项前瞻性、多中心、国际、随机、对照试验,将直接满足SIHD患者对侵入性策略--导管和血管重建--的需求。在400多个部位进行负荷成像后,共有8000名中重度缺血和左心室射血分数为35%的患者入选。基于排除显著左主干病变的需要,符合资格标准的患者将接受盲法冠状动脉CT血管造影术。患者将被随机分到侵入组,如果可行,将接受常规的血管重建和OMT,或者只接受OMT的组。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Judith S Hochman其他文献
1118-102 Baseline white blood cell count and interleukin-6 levels provide complementary prognostic information in acute myocardial infarction: Results from the CARDINAL trial
- DOI:
10.1016/s0735-1097(04)91234-x - 发表时间:
2004-03-03 - 期刊:
- 影响因子:
- 作者:
Manesh R Patel;Kenneth W Mahaffey;Paul W Armstrong;W.Douglas Weaver;Gudaye Tasissa;Judith S Hochman;Thomas G Todaro;Kevin J Malloy;Thomas H Parish;Scottt Rollins;Pierre Theroux;Wiltold Ruzyllo;Jose C Nicolau;Christopher B Granger - 通讯作者:
Christopher B Granger
869-4 Sex disparities in the treatment of non-ST-segment elevation acute coronary syndromes
- DOI:
10.1016/s0735-1097(04)91286-7 - 发表时间:
2004-03-03 - 期刊:
- 影响因子:
- 作者:
Andra L Blomkalns;L.Kristin Newby;Anita Chen;Eric D Peterson;Kelly Trynosky;Deborah Diercks;William E Boden;Matthew T Roe;E.Magnus Ohman;W.Brian Gibler;Judith S Hochman - 通讯作者:
Judith S Hochman
861-1 Direct, selective, factor Xa inhibition in patients with non-ST elevation acute coronary syndromes from the United States, Canada, and Japan: Results of the XaNADU-ACS trial
- DOI:
10.1016/s0735-1097(04)91279-x - 发表时间:
2004-03-03 - 期刊:
- 影响因子:
- 作者:
John H Alexander;Hongqiu Yang;Richard C Becker;Kazuhisa Kodama;Christopher K Dyke;Shaun G Goodman;Neal S Kleiman;Judith S Hochman;Peter B Berger;Eric A Cohen;Michael Lincoff;Edwin G Bovill;Chuichi Kawai;Paul W Armstrong;Robert A Harrington - 通讯作者:
Robert A Harrington
Judith S Hochman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Judith S Hochman', 18)}}的其他基金
The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial EXTENDed Follow-up (EXTEND)
医疗和侵入性方法的比较健康有效性国际研究 (ISCHEMIA) 试验延长随访 (EXTEND)
- 批准号:
10611880 - 财政年份:2021
- 资助金额:
$ 548.98万 - 项目类别:
The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial EXTENDed Follow-up (EXTEND)
医疗和侵入性方法的比较健康有效性国际研究 (ISCHEMIA) 试验延长随访 (EXTEND)
- 批准号:
10379246 - 财政年份:2021
- 资助金额:
$ 548.98万 - 项目类别:
OCCLUDED ARTERY TRIAL--CLINICAL COORDINATING CENTER
动脉闭塞试验--临床协调中心
- 批准号:
7225839 - 财政年份:1999
- 资助金额:
$ 548.98万 - 项目类别:
OCCLUDED ARTERY TRIAL--CLINICAL COORDINATING CENTER
动脉闭塞试验--临床协调中心
- 批准号:
6527429 - 财政年份:1999
- 资助金额:
$ 548.98万 - 项目类别:
相似海外基金
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 548.98万 - 项目类别:
Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 548.98万 - 项目类别:
Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 548.98万 - 项目类别:
Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 548.98万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 548.98万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 548.98万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 548.98万 - 项目类别:
Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 548.98万 - 项目类别:
Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
- 批准号:
23K00129 - 财政年份:2023
- 资助金额:
$ 548.98万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
- 批准号:
2883985 - 财政年份:2023
- 资助金额:
$ 548.98万 - 项目类别:
Studentship